• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

处理威胁下肢的缺血的成本。

The costs of managing lower limb-threatening ischaemia.

作者信息

Singh S, Evans L, Datta D, Gaines P, Beard J D

机构信息

Sheffield Vascular Institute, Northern General Hospital, U.K.

出版信息

Eur J Vasc Endovasc Surg. 1996 Oct;12(3):359-62. doi: 10.1016/s1078-5884(96)80257-7.

DOI:10.1016/s1078-5884(96)80257-7
PMID:8896481
Abstract

One hundred and fifty consecutive patients presenting with limb-threatening ischaemia were studied prospectively to determine treatment and rehabilitation costs in the first year. Limb salvage was attempted in 104 (69%) patients but failed in 13%. Mortality at 1 year was 27%. The cost of treatment, inpatient stay, occupational therapy, physiotherapy, convalescence, disablement services, home adaptations, home care, district nursing, transportation and outpatient visits were determined for each patient. The patients were classified according to their presentation and initial treatment into five groups (number of patients) whose median management costs (interquartile range) for 12 months were: Gp 1 (23 - Revascularisation for acute ischaemia = 3970 pounds (2984-5511) Gp 2 (29) - Angioplasty for critical ischaemia = 6611 pounds (3630-10,200) Gp 3 (52) - Reconstruction for critical ischaemia = 6766 pounds (4337-9677) Gp 4 (34) - Primary amputation = 10,162 pounds (7894-13,026) Gp 5 (12) - Primary bilateral amputations = 13,848 pounds (11,440-18,056) At 1 year, there was no significant difference in the cost of managing a patient with a critically ischaemic limb by angioplasty or surgical reconstruction. The cost of revascularisation for acute ischaemia was comparatively low because these patients required minimal rehabilitation. The median cost of managing a patient following amputation was almost twice that of successful limb salvage justifying an aggressive revascularisation policy. However, justification of such a policy on economic grounds requires salvage failure episode to be minimised as they increase costs considerably.

摘要

对150例出现肢体威胁性缺血的连续患者进行了前瞻性研究,以确定第一年的治疗和康复费用。104例(69%)患者尝试进行保肢治疗,但13%失败。1年时的死亡率为27%。确定了每位患者的治疗费用、住院时间、职业治疗、物理治疗、康复、残疾服务、家庭改造、家庭护理、社区护理、交通和门诊就诊费用。根据患者的表现和初始治疗将患者分为五组(患者数量),其12个月的管理费用中位数(四分位间距)为:第1组(23例 - 急性缺血血管重建)= 3970英镑(2984 - 5511英镑);第2组(29例 - 严重缺血血管成形术)= 6611英镑(3630 - 10200英镑);第3组(52例 - 严重缺血重建)= 6766英镑(4337 - 9677英镑);第4组(34例 - 一期截肢)= 10162英镑(7894 - 13026英镑);第5组(12例 - 一期双侧截肢)= 13848英镑(11440 - 18056英镑)。1年时,通过血管成形术或手术重建治疗严重缺血肢体患者的费用没有显著差异。急性缺血血管重建的费用相对较低,因为这些患者所需的康复最少。截肢后管理患者的费用中位数几乎是成功保肢费用的两倍,这证明了积极的血管重建政策的合理性。然而,基于经济理由证明这种政策的合理性需要将保肢失败事件降至最低,因为它们会大幅增加成本。

相似文献

1
The costs of managing lower limb-threatening ischaemia.处理威胁下肢的缺血的成本。
Eur J Vasc Endovasc Surg. 1996 Oct;12(3):359-62. doi: 10.1016/s1078-5884(96)80257-7.
2
Surgery for limb threatening ischaemia: a reappraisal of the costs and benefits.肢体威胁性缺血的手术治疗:成本与效益的重新评估
Eur J Vasc Endovasc Surg. 1995 Feb;9(2):181-8. doi: 10.1016/s1078-5884(05)80088-7.
3
Surgical treatment for chronic critical leg ischaemia: a 5 year follow-up of socioeconomic outcome.慢性严重下肢缺血的外科治疗:社会经济结局的5年随访
Eur J Vasc Endovasc Surg. 1997 May;13(5):452-9. doi: 10.1016/s1078-5884(97)80172-4.
4
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis.BASIL 试验:下肢严重缺血旁路与血管成形术的比较:健康相关生活质量结局、资源利用和成本效益分析。
J Vasc Surg. 2010 May;51(5 Suppl):43S-51S. doi: 10.1016/j.jvs.2010.01.076.
5
A prospective study of the effect of limb-threatening ischaemia and its surgical treatment on the quality of life.一项关于肢体威胁性缺血及其手术治疗对生活质量影响的前瞻性研究。
Eur J Vasc Endovasc Surg. 1997 Mar;13(3):306-14. doi: 10.1016/s1078-5884(97)80103-7.
6
Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial.多中心随机对照临床试验,旨在比较旁路手术优先与球囊血管成形术优先血运重建策略治疗下肢严重缺血(因下肢动脉疾病所致)的临床效果和成本效益。该试验名为“下肢严重缺血旁路与血管成形术(BASIL)”。
Health Technol Assess. 2010 Mar;14(14):1-210, iii-iv. doi: 10.3310/hta14140.
7
Trends in the national outcomes and costs for claudication and limb threatening ischemia: angioplasty vs bypass graft.跛行和肢体威胁性缺血的国家结局和成本趋势:血管成形术与旁路移植术。
J Vasc Surg. 2011 Oct;54(4):1021-1031.e1. doi: 10.1016/j.jvs.2011.03.281. Epub 2011 Aug 31.
8
Management cost of acute limb ischaemia.急性肢体缺血的管理成本。
Br J Surg. 1996 Oct;83(10):1390-3. doi: 10.1002/bjs.1800831020.
9
Perioperative and rehabilitative outcomes after amputation for ischaemic leg gangrene.缺血性腿部坏疽截肢术后的围手术期及康复结局
Ann Acad Med Singap. 2000 Mar;29(2):168-72.
10
Critical limb ischaemia in patients over 80 years of age: options in a district general hospital.80岁以上患者的严重肢体缺血:地区综合医院的治疗选择
Br J Surg. 1995 Oct;82(10):1361-3. doi: 10.1002/bjs.1800821022.

引用本文的文献

1
Analysis of the Peri-Operative Cost of Non-Traumatic Major Lower Extremity Amputation in Jordan.约旦非创伤性下肢大截肢手术围手术期成本分析
Clinicoecon Outcomes Res. 2020 Jan 9;12:13-21. doi: 10.2147/CEOR.S232779. eCollection 2020.
2
Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery.药物涂层球囊治疗股浅动脉病变的成本效果分析。
J Vasc Surg. 2018 Jan;67(1):343-352. doi: 10.1016/j.jvs.2017.06.112. Epub 2017 Sep 27.
3
Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) Trial.
严重肢体缺血患者最佳血管内治疗与最佳手术治疗对比试验(BEST-CLI)的设计与原理
J Am Heart Assoc. 2016 Jul 8;5(7):e003219. doi: 10.1161/JAHA.116.003219.
4
Cost-effectiveness of medical, endovascular and surgical management of peripheral vascular disease.外周血管疾病的药物、血管内及手术治疗的成本效益
Cardiovasc Revasc Med. 2015 Oct-Nov;16(7):421-5. doi: 10.1016/j.carrev.2015.06.006. Epub 2015 Jul 9.
5
Criticial limb ischemia: epidemiology.严重肢体缺血:流行病学
Methodist Debakey Cardiovasc J. 2012 Oct-Dec;8(4):10-4. doi: 10.14797/mdcj-8-4-10.
6
TRICKS magnetic resonance angiography at 3-tesla for assessing whole lower extremity vascular tree in patients with high-grade critical limb ischemia: DSA and TASC II guidelines correlations.3特斯拉磁共振血管造影术的TRICKS技术用于评估严重下肢缺血患者的整个下肢血管树:与数字减影血管造影及TASC II指南的相关性
ScientificWorldJournal. 2012;2012:192150. doi: 10.1100/2012/192150. Epub 2012 Dec 11.
7
Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia.自体骨髓单核细胞治疗安全,可提高临界肢体缺血患者免于截肢的生存率。
J Vasc Surg. 2011 Jun;53(6):1565-74.e1. doi: 10.1016/j.jvs.2011.01.074. Epub 2011 Apr 22.
8
Calcanisation of tibia using Ilizarov fixator in crush injuries of hindfoot: a new method.在后足挤压伤中使用伊利扎罗夫固定器进行胫骨钙化:一种新方法。
Int Orthop. 2008 Dec;32(6):779-84. doi: 10.1007/s00264-007-0400-3. Epub 2007 Jul 17.
9
A national and single institutional experience in the contemporary treatment of acute lower extremity ischemia.当代急性下肢缺血治疗的全国性单机构经验。
Ann Surg. 2003 Sep;238(3):382-9; discussion 389-90. doi: 10.1097/01.sla.0000086663.49670.d1.